Docket #: S25-302
Therapeutic Approach for Benign Uterine Conditions
Stanford researchers have identified a therapeutic approach for benign uterine conditions. The approach targets the endometrium directly rather than the hormonal environment that sustains them.
Evidence supporting this concept has been established in human endometrial cell models and in animal models.
Stage of Development
Preclinical
Applications
- Therapeutic for benign uterine conditions
- Alternative for patients who cannot tolerate or do not respond to standard of care
Advantages
- Mechanism distinct from current standard of care
- Preclinical proof of concept in human cell models and an animal model
Related Links
Similar Technologies
-
Targeting Cancer Stem Cell Metabolism via Isoform-specific ALDH1B1 and ALDH1A3 Inhibitors S20-218Targeting Cancer Stem Cell Metabolism via Isoform-specific ALDH1B1 and ALDH1A3 Inhibitors
-
Potent Patched1 (PTCH1) nanobody TI23 for the activation of the Hedgehog signaling pathway S19-418Potent Patched1 (PTCH1) nanobody TI23 for the activation of the Hedgehog signaling pathway
-
Injectable Supramolecular Hydrogels for Bioprinting, Wound Healing, and Drug Delivery S20-136Injectable Supramolecular Hydrogels for Bioprinting, Wound Healing, and Drug Delivery